Davide Campari-Milano N.V. (MIL:CPR) reported H1 2026 net profit €129m and sales €1.51bn (+2.7% organic), with adj. EBIT €358m and raised EBIT margin guidance while reaffirming ~3% organic sales growth; Lagfin bought ~64% of €536.4m 2028 Campari exchangeable bonds, which were cancelled after settle…
H1 2026 saw 2.7% organic sales growth, margin expansion, and strong share gains in priority brands across most markets. Portfolio streamlining and innovation supported profitability, while guidance for full-year growth and margins was confirmed, with logistics and tariffs as key risks.Based on Davi…
Net sales declined 1.0% to €1,512m in H1 2026, but organic growth was 2.7% and adjusted net profit rose 4.7% to €226m. Portfolio streamlining and non-recurring charges weighed on reported profit, while leverage remained stable and brand investments increased.Original document: Davide Campari-Milano…
Organic topline grew 2.7% in H1 2026, with gross margin up 130bps and EBIT-adjusted margin expanding. Strong performance in aperitifs and agave offset whiskey declines, while portfolio streamlining and new financing improved focus and funding. Leverage stable at 2.6x.Original document: Davide Campa…
